Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
Tislelizumab combined with chemotherapy has shown good efficacy and safety in clinical
studies of lung adenocarcinoma (RATIONALE 304) and lung squamous cell carcinoma (RATIONALE
307), thus has been approved as the first-line therapy for advanced non-small cell lung
cancer (NSCLC) in China. However, there is no data in the field of neoadjuvant therapy for
NSCLC. This single-arm, single-center phase II clinical study is designed to evaluate the
efficacy, safety and major pathological response (MPR) of Tislelizumab combined with
chemotherapy as neoadjuvant therapy in patients with stage IIIA-IIIB (N2) lung squamous cell
carcinoma. Biomarkers correlated with efficacy outcomes will also be explored.